Ask AI
ProCE Banner Activity

Highlights in Leukemias and Lymphomas From the 2026 EHA Congress

Conference Coverage
Clinical Thought

The EHA 2026 Congress was a platform to compelling data for a potential new standard-of-care pirtobrutinib combination for R/R CLL (BRUIN CLL-322), promising use of menin inhibitors with induction therapy for AML (KOMET-007), final long-term update for CLL14, treatment optimization approaches for AML (OPTI-AML) and LR-MDS (MAXILUS, EPO-PRETAR), and early data for surovatamig for FL (SOUNDTRACK-F1), a BTK degrader for CLL (CaDAnCe-101), and a type II JAK2 inhibitor for myelofibrosis (AJX-101).

Released: August 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at EHA 2026

Financial Disclosures

Primary Author

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Cullinan, Daiichi Sankyo, Geron, Johnson & Johnson, Kura/Kirin Kyowa, Menarini/Stemline, Novartis, Servier, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.